Next 10 |
home / stock / asnd / asnd articles
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 43.24% on an annualized basis producing an average annual retur...
With U.S. stock futures trading higher on Friday morning, some of the stocks that may grab investor focus today are as follows: Arkhouse Managemen...
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 15.29% on an annualized basis producing an average annual retur...
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 16.47% on an annualized basis producing an average annual retur...
COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that it will host informational booths, ...
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 41.19% on an annualized basis producing an average annual retur...
Tuesday, Ascendis Pharma A/S (NASDAQ:ASND) announced that the FDA extended the review date for TransCon PTH (palopegteriparatide) for adu...
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 16.63% on an annualized basis producing an average annual retur...
COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report first quarter 2024 fina...
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...